EN DE
Watch Cytogen Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cytogen Inc (217330) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Cytogen Inc stock KRW 716, price KRW 2,205, that is 67.5% below the price, quality 33 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7217330000

CI Cytogen Inc logo Thin data Nov 9, 2026

Cytogen Inc

217330 · KQ
Very expensive, weak quality

Our calculation puts a fair price 68% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +109.7 %/yr in KRW)
Fair value 715.61 KRW · Strongly overvalued
Quality 33/100
Loss-making · -38.5% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 9/100
Thin data
Watch Cytogen Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

22,400 KRW 2,205 KRW Fair Value 715.61 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range 2,205 KRW – 22,400 KRW · fair‑value band 472.30 KRW – 894.51 KRW · the 2,205 KRW price screens above the 715.61 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Cytogen in your weekly email

Every Wednesday you see whether Cytogen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea.

Show moreShow less

The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies.

The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.

Stock analysis

Cytogen Inc (217330) currently trades at 2,205 KRW, while our model-based Fair Value estimate is 715.61 KRW, 68% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 93/100, which puts the data coverage at low.

Scenario range: 472.30 KRW (bear) to 894.51 KRW (bull), the price of 2,205 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cytogen Inc reported revenue of 26.1B KRW in FY2025 versus 348M KRW in FY2021, a compound +194.2%/yr. Reported net income was −12.3B KRW in FY2025.

Key figures

Market cap 50.9B KRW (≈ $37.6M) Micro · P/S ratio 1.98 · EPS (TTM) −456.09 KRW · Net margin −38.5% · Return on equity −27.4% · Return on assets (EBIT) −20.2% (5-year average) · Operating margin −17.8% · Revenue (TTM) 27.4B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 77% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −68%, 217330 screens richer than that median.

Fair Value models

Bear 472.30 KRW Fair Value 715.61 KRW Bull 894.51 KRW
Price 2,205 KRW · Downside -67.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 472.30 KRW 715.61 KRW 894.51 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 472.30 KRW 715.61 KRW 894.51 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 79
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 56
Debt, balance sheet and risk of trouble
Investment 31
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+138.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+224.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+109.7%
Start year 2020 (pandemic). Over 10 years: +48.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,024.9% (2020) → −28.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

217330 screens overvalued: fair value 68% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Cytogen Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −67.5% · Bottom 25%
Profitability
Return on assets −19.8% · Bottom 25%
Net margin (12 months) −38.5% · Bottom 25%
Operating margin (12 months) −17.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 8.7% · Above median
Balance sheet
Debt / equity 0.30× · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 1.43× · Cheaper than median
P/S (12 months) 1.86× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)44 · sector 39
PAST (return on equity)0 · sector 15
HEALTH (low debt)85 · sector 95
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs 217330
IQVIA Holdings IQV $271.83 $299.01 +10% vs 217330
Illumina, Inc ILMN $213.13 $234.44 +10% vs 217330
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs 217330
Danaher Corporation DHR $230.25 $209.18 −9% vs 217330
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs 217330
Mettler-Toledo International Inc MTD $1,722 $655.06 −62% vs 217330
Agilent Technologies, Inc A $174.76 $64.53 −63% vs 217330
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs 217330
Waters Corporation WAT $457.60 $91.26 −80% vs 217330

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cytogen Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cytogen Inc Fair Value". https://www.fairvalue-calculator.com/stock/217330

Frequently asked questions

Is Cytogen Inc (217330) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 715.61 KRW versus a price of 2,205 KRW, about 68% lower (overvalued).
What is the fair value of 217330?
Our model-based fair value for Cytogen Inc is 715.61 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 2,205 KRW.
What is the quality score of 217330?
Cytogen Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cytogen Inc (217330)?
Our model-based price target is the fair value of 715.61 KRW (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 472.30 KRW, optimistic scenario 894.51 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Cytogen Inc stock forecast for 2026?
Our models put fair value at 715.61 KRW, about 68% lower versus a price of 2,205 KRW (overvalued). Cautious scenario 472.30 KRW, optimistic scenario 894.51 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Cytogen Inc (217330)?
Cytogen Inc reported trailing-twelve-month revenue of about 27.4B KRW (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Cytogen Inc (217330)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cytogen Inc it is 715.61 KRW per share (as of Nov 9, 2026), against a price of 2,205 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Cytogen Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 217330 trades above its calculated fair value: price 2,205 KRW, fair value 715.61 KRW, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 217330?
No. The price is what the market pays today (2,205 KRW); the fair value is what the company's own numbers justify (715.61 KRW). For Cytogen Inc the two are 1,489 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Cytogen Inc worth?
The market values Cytogen Inc at about 50.9B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 2,205 KRW; our models calculate a fair value of 715.61 KRW per share.
What do the bullish and bearish scenarios say about 217330?
Our models span a range for Cytogen Inc: cautious scenario 472.30 KRW, base 715.61 KRW, optimistic 894.51 KRW per share (as of Nov 9, 2026, price 2,205 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cytogen Inc (217330)?
Balance-sheet figures for Cytogen Inc (as of Nov 9, 2026): return on equity −27.4%, debt of 0.30 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 217330 from its 52-week high?
Cytogen Inc trades at 2,205 KRW, about 77% below its 52-week high of 9,420 KRW and at the low of 2,205 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 715.61 KRW is for.
Which stocks are comparable to Cytogen Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cytogen Inc stock attractive at the current price?
The data as of Nov 9, 2026: price 2,205 KRW, calculated fair value 715.61 KRW (−68%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 217330 calculated?
We run Cytogen Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 715.61 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cytogen Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cytogen Inc (217330)?
The closing price on Nov 6, 2026 was 2,205 KRW. Our model-based fair value is 715.61 KRW, about 68% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cytogen Inc right now?
The price sits above even our optimistic bull case (894.51 KRW). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (472.30 KRW to 894.51 KRW) leaves room in how you read the outcome.

Key figures of Cytogen Inc

How large is the market capitalisation of Cytogen Inc (217330)?
The market capitalisation of Cytogen Inc is 50.9B KRW (≈ $37.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cytogen Inc (217330)?
The price-to-sales ratio of Cytogen Inc is 1.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cytogen Inc (217330)?
Earnings per share at Cytogen Inc are −456.09 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cytogen Inc (217330)?
The net margin of Cytogen Inc is −38.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cytogen Inc (217330)?
The return on equity (ROE) of Cytogen Inc is −27.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cytogen Inc (217330)?
On an EBIT basis the return on assets of Cytogen Inc is −20.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cytogen Inc (217330)?
The operating margin of Cytogen Inc is −17.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cytogen Inc (217330)?
Revenue at Cytogen Inc is growing +8.7% versus a year earlier (3y avg +225%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cytogen Inc (217330) generate?
The free cash flow of Cytogen Inc is −9.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cytogen Inc (217330) carry?
The net debt of Cytogen Inc is 4.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cytogen Inc in the live analysis

One click puts Cytogen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.